Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00227305
Status:
COMPLETED
Last Update Posted:
2013-01-08
First Post:
2005-09-27
Brief Title:
Quetiapine Fumarate SEROQUEL in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 26-week Multicenter Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate SEROQUEL Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia Abbreviated
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANCHOR 150
Brief Summary:
The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate SEROQUEL in the treatment of adolescent patients with schizophrenia and bipolar I disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None